Acceleron Pharma’s Chief Medical Officer Robert Zeldin Departs

Robert Zeldin has left Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), where he was executive vice president and chief medical officer. Cambridge, MA-based Acceleron gave no reason for Zeldin’s departure, which comes just nine months after he joined the company. A search for Zeldin’s successor is underway.

Last week, Acceleron and partner Celgene (NASDAQ: [[ticker:CELG]]) filed for FDA approval of luspatercept, a drug developed to treat anemia in patients who have myelodysplastic syndromes or beta thalassemia. Separately, Acceleron also stopped development of neuromuscular drug ACE-2494 after reviewing Phase 1 data.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.